Patronus AI unveiled “Generative Simulators,” adaptive “practice worlds” that replace static benchmarks with dynamic ...

November's wave of FDA oncology approvals signals the industry's shift toward platform-based precision therapies over broad-spectrum approaches([1]) . The global anticancer drug market now values ...

November's wave of FDA oncology approvals signals the industry's shift toward platform-based precision therapies over broad-spectrum approaches([1]) . The global anticancer drug market now values ...

The lack of gains in productivity from AI could stall adoption and burst the economic bubble. Is there a rational explanation ...

Calling for a revival of the concept of a co-operative commonwealth as a “solidarity stack” to reshape AI, he added: “Integrity can be world changing … we can show the co-operative principles by ...

The clinical-stage biotech might have a successful drug on its hands, if a relatively early-stage clinical trial is any indication. Its REC-4881 did very well in the testing. 10 stocks we like better ...

In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up for any (or all) of our 25+ Newsletters. Some states have laws and ethical rules regarding solicitation and ...

Hi, everyone, and welcome. I'm Najat Khan, Recursion's Chief R&D and Chief Commercial Officer and incoming CEO and President. Let's jump right in. Today is an important moment for Recursion, for our ...